Gilead Sciences (NASDAQ: GILD) reported Q4 EPS of $2.19, $0.04 better than the analyst estimate of $2.15. Revenue for the quarter came in at $7.42 billion versus the consensus estimate of $7.33 billion.

GUIDANCE:

Gilead Sciences sees FY2021 EPS of $6.75-$7.45, versus the consensus of $7.05.

• Product Sales including Veklury of $23.7 billion to $25.1 billion -
• - Operating expenses flat to low single-digit percentage decline -
  

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.